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ABSTRACT
In-stent restenosis after stenting in vascular occurs secondary to the 
accumulation of smooth muscle cell and extracellular matrix. This condition is a 
major complication caused by the occurrence of neointimal hyperplasia (NIH). 
The study aimed to prove the role of miRNA-21 as a risk predictor of the NIH 
event in aorta of rabbits animal model who underwent bare metal (BM) type 
stent implantation and to know the miRNA-21 role in IL-6 and IL-8 expressions. 
This study was quasi experimental, coducted in Catheterization Laboratory 
Dr. Sardjito General Hospital Yogyakarta. Stent implantation was observed 
intravascular ultrasonography. Blood vessel which was already deployed by 
stent taken as sample for pathologic examination. Rabbit blood samples were 
collected on  day 0, 7, and 28. Quantification miRNA-21 expression has been 
done with qPCR and ELISA approach. These 10 rabbits divided into two groups 
in which one group as control (without stent deployment, 4 models) and 
another group as intervention (with BM type stent deployment, 6 models). The 
increase in expression of miRNA-21 on the day 7 and day 28 in the intervention 
group compared to the control group. Neointimal hyperplasia increased in 
intervention group on day 7, and 28 were from mild grade to moderate, and 
severe respectively. In addition, levels of IL-6 and IL-8 increased on day 28 
compared with on day 7. This study showed increase of miRNA-21 expression 
on day 7 and NIH rise from the mild to moderate. Furthermore, on day 28, that 
increases of miRNA-21 expression and NIH rose from to moderate to severe. 
The increase of miRNA-21 was also shown on day 7 and  28 followed by the 
increase of IL-6 and IL-8 levels. 
ABSTRAK
In-sten restenosis setelah proses pemasangan sten pada vaskular terjadi akibat 
akumulasi sel otot polos dan matriks ekstraselular. Kondisi ini merupakan 
komplikasi utama yang disebabkan oleh terjadinya neointimal hyperplasia 
(NIH). Penelitian ini bertujuan untuk membuktikan peran miRNA-21 sebagai 
prediktor risiko NIH pada aotrta dari model hewan kelinci yang diperlakukan 
implantasi stent tipe bare metal (BM) dan miRNA-21 pada ekspresi IL-6 
dan IL-8. Penelitian ini merupakan experimen quasi yang dilaksanakan di 
Laboratorium Catheterisasi, RSUP Dr. Sardjito Yogyakarta. Implantasi sten 
diamati dengan intravascular ultrasonografi. Pembuluh darah yang telah 
dipasangi dengan stent diambil sebagai sampel untuk pemeriksaan patologi. 
Darah kelinci dikumpulkan pada hari ke 7 dan 28. Kuantifikasi ekspresi 
miRNA-21 dilakukan dengan metode qPCR dan ELISA. Kelinci sebanyak 10 
ekor dibagi menjadi dua kelompok. Kelompok kontrol sebanyak 4 ekor tanpa 
pemasangan stent. Kelompok perlakuan sebanyak 6 ekor dengan pemasangan 
stent tipe BM. Ekspresi miRNA-21 meningkat pada hari ke 7 dan 28 pada 
kelompok perlakuan dibandingkan kontrol. Peningkatan NIH pada kedua 
kelompok pengamatan hari ke 7 dan 28   tergolong ringan, sedang hingga 
berat. Kdar IL-6 dan IL-8 juga mengalami kenaikan. Ekspresi miRNA-21 
meningkat hari ke 7 dan NIH meningkat dari ringan hingga sedang. Pada hari 
ke 28 terjadi peningkatan ekspresi miRNA-21 dan NIH dari sedang menjadi 
berat. Penigkatan miRNA-21 juga terlihat pada hari ke 7 dan 28 dengan disertai 
kenaikan kadar IL-6 dan IL-8.
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INTRODUCTION
Cardiovascular diseases which 
have high morbidity and mortality 
are considered having high global 
burden every year. According to WHO, 
in 2015 it was estimated deaths from 
cardiovascular diseases would be 
increased to 20 million. Nearly one third 
of the incidence of global deaths is due 
to cardiovascular diseases.1 Based on 
WHO (2011), death from coronary heart 
disease (CHD) reached 234,000 or 17.05% 
of total death in Indonesia. The age-
adjusted death rate is 150.77 per 100,000 
population which ranks Indonesia 51 in 
the world.2
Combination of lifestyle 
modification, medical procedures and 
invasive procedure to open or dilate the 
narrowed or blocked coronary arteries 
are the therapeutic choices of CHD. 
Percutaneous intervention in which 
considered as invasive procedures 
including angioplasty using balloons 
and other invasive procedure like stent 
placement in the coronary arteries. 
Percutaneous coronary intervention 
(PCI) is a therapeutic revolution that 
develops rapidly and very important in 
CHD patients where previous coronary 
blood flow is lacking or even completely 
blocked so that the vessel becomes open.3
Some issues are still open and 
represent a chalenge despite continuous 
technical advances in stent restenosis 
(ISR). This condition is a major 
complication caused by the occurrence 
of neointimal hyperplasia (NIH).3 The 
pathophysiological mechanism of 
restenosis is still not well explained, but 
it is believed that various mechanisms 
involved including inflammation, 
proliferation and remodeling of 
the matrix. In recent years, several 
clinical, biological, genetic, epigenetic 
predictors have been identified related 
to lesions and procedural risk factors for 
restenosis.4
Hence, early detection and 
prevention of restenosis to produce 
better clinical outcomes are needed. 
Reliable biomarker in which considered 
minimal invasive measurement is one 
of the modality. Currently, a micro-
ribonucleic acid (miRNA) attracts the 
attention of researchers in the world due 
to its role in ISR. The miRNA is small RNA, 
with a length of 20-25 nucleotides, single 
stranded and have no role in encoding 
proteins, yet play a role in regulating 
target gene expression at the post 
transcription level. It further reduces 
protein expression by blocking the 
translation of mRNA and by promoting 
proteins degradation.5
miRNA has the ability to regulate 
systemic functions such as inflammatory 
responses.6 This role is prominent in the 
initiation and resolution of inflammation 
after the onset of vessel injury.7 miRNA is 
very important because its involvement 
in various biological processes in NIH 
after the installation of coronary stents. 
miRNA also detected in the blood 
circulation and may be useful as a 
biomarker for cardiovascular diseases.8
Various miRNAs have the function 
of downregulation the inflammatory 
pathways, which are biologically 
useful for controlling the inflammatory 
process by targeting specific proteins.9 
Modulation over miRNA-21 expression 
in vitro, with depletion has a negative 
effect from neointimal lesion formation. 
In vitro expression of miRNA-21 levels 
shows significantly higher in vascular 
smooth muscle cells differentiated than 
non-differentiated cells. Depletion or 
decrease of miRNA-21 causes a decrease 
in proliferation and increase apoptosis of 
the cells. The cellular effect of miRNA-21 
was shown by in vivo studies of carotid 
arteries of rats that had lesions induced 
by balloon intervention. Moreover, 
analysis with westernblot shows that 
PTEN and Bcl-2 are the target proteins of 
miRNA-21 cellular effects. These results 
indicate that miRNA-21 regulates and 
stimulates the formation of neointimal 
lesions.10
MiRNA-21 plays an important role in 
vascular inflammation promotion and 
lesion remodeling after stent insertion 
in pig animal model.7 Anti miRNA-21 
inhibits the proliferation of vascular 
smooth muscle cells both in vitro and 
in vivo.3 Depend on the presence of a 
stimulus, vascular smooth muscle cells 
are able to turn into a proliferative or 
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differentiate state. This study aimed 
to prove the role of miRNA-21 as a risk 
predictor of the NIH event in aorta rabbits 
animal model who underwent BM type 
stent implantation and to evaluate 
the miRNA-21 role in IL-6 and IL-8 
expressions. It is expected that miRNA-21 
can be used as an early predictor of the 
occurrence of neo-intimal hyperplasia 
after BM stent installation.
MATERIALS AND METHODS
Animal model
Design of this study is quasy.We used 
male Oryctolagus cuniculus rabbits, 4 
rabbits as control group and 6 rabbits 
as treatment group. Study had been 
done in Catheterization Laboratory Dr. 
Sardjito General Hospital, Yogyakarta. 
Stent implantation and intravascular 
ultrasonography performed to observe 
and ensure the position and stent 
deployment were optimized. 
Protocol of study
Blood vessel which was already 
deployed by stent was taken as sample 
for pathologic examination. Thickening 
of the NIH measured by accounting the 
number of smooth muscle cells that 
arranged in the inner lines of the lumen 
of the artery by microscop observations 
on cross sectional vascular preparation. 
All sprocedures were performed by 
certified operators with standard 
operation procedures. Protocol of the 
study has been approved by the Research 
Ethics Committee for Animal Laboratory 
of the Integrated and Testing Laboratory 
(Laboratorium Penelitian dan Pengujian 
Terpadu/LPPT), Universitas Gadjah Mada 
Yogyakarta number 00030/04/LPPT/
VI/2016.
Blood samples were collected from 
the rabbit ear on day0, day 7, and day 28. 
There is no predetermine time collection 
since there is still not any references 
taken into account the best time to collect 
miRNA in blood sample. Quantification 
expression had done in several steps 
with qPCR and ELISA approach. 
Quantification of miRNA was calculeted 
with qPCR and quantification of IL 
using ELISA. The primers for miRNA-24 
were CGCCTGGCTCAGTTCAGCA 
(forward) GCAGCTCTTCATTTACGGTCCA 
(reverse), for miRNA-2 was 
GCACCGTCAAGGCTGAGAAC (forward) 
and CAGCCCATCGACTGGTG (reverse) 
with 40 cycles. Smooth muscle cell 
quantified using smooth muscle cell-
actin staining. ELISA kits FineTestwere 
used for IL quantification catalogue 
number ERB0068 for IL-6 and catalogue 
number ERB0069 for IL-8. 
Statistical analysis
Data were presented as mean ± 
standard error of the mean (SEM) and 
analysed using SPSS version 23. A p 
value < 0.05 was considered significance. 
RESULTS
Ten O. cuniculus male rabbits was 
used in this study. The rabbits divided 
into two groups i.e.  control grou without 
stent deployment and treatment group 
with BM type stent deployment. The 
characteristics the animal models are 
presented in TABLE 1. No any abnormality 
and differences between two groups 
in terms of nutrition and hematology 
profile were observed. Medication were 
different between those two groups as 
consequence of stent deployment. Aspirin 
and clopidogrel have been administered 
since 7 days before and after 28 days after 
intervension. After the trial was done, 
all rabbits were euthanased according to 
standard procedure.
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TABLE 1. Characteristics of animal models
Parameters Control group
(n=4)
Treatment group
(n=6)
Rabbit type O. cuniculus O. cuniculus
Age (mean ± SEM months) 8.1± 0.13 8.2±0.15
Male sex (%) 100 100
Weight (mean ± SEM kg) 3.9 ±0.43 3.9±0.48
Nutrition status Fair Fair
Hematology profile
•	 Hemoglobin 10.8±0.86 11.2±2.47
•	 Leukocyte count 6.9±2.70 7.8±5.4
•	 Ureum 20.7±7.43 16.0±2.72
•	 Creatinine 0.8±1.15 1.90±0.41
Medication
•	 Placebo Yes No
•	 Aspirin (mg/kg/day) No 1
•	 Clopidogrel (mg/kg/day) No 1
Cycle quantification was done in 
miRNA-21 (TABLE 2) which shown that 
there were no differences between day 
0, 7, and 28 in control group (p>0.05). The 
miRNA-21 expression were significantly 
increase after intervention with BM 
type stent compared with control group 
on day7 (5.77 ± 0.67 versus 1.50 ± 0.59, 
p=0.001; 95%CI 2.830-5.697) and day 28 
(7.31 ± 0.41 versus 1.73 ± 0.44; p =0.009; 
95%CI 4.605-6.554). The increase of the 
miRNA-21 after intervention with BM 
type stent was also observed on day28 
(7.31 ± 0.41) compared with on day7 (5.77 
± 0.67) as shown on TABLE 3 and FIGURE 
1. However, it was not significntly 
different (p = 0.092).
TABLE 2.  Expression quantification result 
by Cq (cycle quantification) 
miRNA in control group
Days miRNA-21 ± SEM
0 35.68 ± 0.13
7 35.72 ± 0.16
28 33.79  0.58
p 0.87a;  0.37b;  0.26c
aControl on day0 versus intervention 
in day 7; bControl on day0 versus 
intervention in day 28; cControl on 
day7 versus intervention in day 28
TABLE 3. Differences of miRNA-21 expression between 
intervention and control group on day7, and day 28.
Days Control group Intervention group p (95%CI)
7 1.50 ± 0.59 5.77 ± 0.67 0.001 (2.830-5.697)
28 1.73 ± 0.44 7.31 ± 0.41 0.009 (4.605-6.554)
p 0.260 0.092
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FIGURE 1. Level of miRNA-21 expression (fold change) on day0, 7, and 28 
between control and intervention group.
TABLE 4. Number of vascular smooth muscle cells both in control and 
intervention groups 
Observation Mean ± SD p
Days 0
•	 Control 11.00 ± 0.00
•	 Intervention -
Day 7
•	 Control 10.00 ± 0.00
•	 Intervention 14.88 ± 3.15 0.397a; 0.311b
Days 28
•	 Control 10.16 ± 1.64
•	 Intervention 28.19 ± 4.72 0.079c; 0.0.015d; <0.016e; 0.016f
aControl group on day0 versus intervention on day7; bControl 
group on day7 versus intervention on day7; cControl group on day7 
versus intervention on day28; dIntervention group on day7 versus 
intervention on day28; eComparison control group day 28 with 
intervention group day 28.
Vascular smooth muscle cells 
number also measured in control group 
with the lowest number was 8 and the 
highest was 13. Intervention with BM 
type stent  (intervention group) showed 
10 as the lowest number while 35 as the 
highest number (TABLE 4).
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Three categories are divided based 
on these numbers by tertiel percentage 
(TABLE 5) to show the severity of NIH.
TABLE 5. Three divided categories 
between vascular smooth 
muscle cells
Severity of neo 
intima hyperplasia
Vascular smooth 
muscle cells
Mild 8 - 11
Moderate 12 - 16
Severe 17 - 35
The mean of NIH in control group 
from day 0, intervention group day 7, 
and intervention group day 28 was 10.38 
± 0.37 (mild), 14.88 ± 1.04 (moderate), 
and 28.19 ± 2.37 (severe) respectively. 
Significantly increase of NIH between 
intervention group on day28 compared 
with on day7 was observed (p = 0.004; 
95% CI -3.94 – 17.68). 
The level of IL-6 between control 
and intervention group on day0, 7 and 
28 are shown on TABLE 6 or FIGURE 2. 
In general, there was no significantly 
different of the level of IL-6 between 
control group on day0, 7 and 28 
compared with intervention group on 
day0, 7 and 28 (p>0.05), except the level 
of IL-6 between control group on day0 
compared with intervention group on 
day28 (p = 0.005). 
TABLE 6. IL-6 level (mean ± SEM ng/L)  0, 7, and 28 both in control and 
intervention group
Group n IL-6 p
Control group day 0 3 0.08 ± 0.02
Control group day 7 1 0.04 0.19a
Control group day 28 1 0.09 0.005b
Intervention group day 7 3 0.32 ± 0.15 0.18c 
Intervention group day 28 3 0.50 ± 0.07 0.18d; 0.51e 
SEM = standart error of the mean; aComparison control group day 0 and 
intervention group day 7; bComparison control group day 0 and intervention 
group day 28; cComparison control group day 7 and intervention group 
day 7; dComparison control group day 28 and intervention group day 28; 
eComparison intervention group day 7 and intervention group day 28
FIGURE 2. Level of IL-6 in days 0,7, and 28 between control and 
intervention group
 Day of observation 
 
IL-6 
level 
(ng/
mL) 
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TABLE 7. IL-8 level (mean ± SEM ng/mL) on day0, 7, and 28 both 
in control and intervention group
Group n IL-8 p
Control group day 0 3 0.37 ± 0.10
Control group day 7 1 0.49
Control group day 28 1 0.32
Intervention group day 7 3 1.47 ± 0.06 0.001a; 0.18b
Intervention group day 28 3 2.24 ± 0.04 <0.001c; <0.05d; 0.18e
SEM = standard error of the mean; aComparison control group day 
0 and intervention group day 7; bComparison control group day 7 
and intervention group day 7; cComparison control group day 0 and 
intervention group day 28; dComparison intervention group day 7 and 
intervention group day 28; eComparison control group day 28 and 
intervention group day 28.
FIGURE 3. Level of IL-8 in day 0, 7, and 28 between control and intervention group
The level of IL-8 between control 
and intervention group on day0, 7 and 
28 are shown on TABLE 7 or FIGURE 
3. Significantly different in the level of 
IL-8 between control group on day0 and 
intervention group on day7 (p=0.001), 
between control group on day0 and 
intervention group on day28 (p<0.001) as 
well as intervention group on day7 and 
intervention group on day18 (p<0.05) 
were observed. 
 
IL-8 
level 
(ng/
mL) 
 Day of observation 
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DISCUSSION
miRNA-21 expression after 
intervention with BM type stent 
significantly increased 5.77 times on day 
7 (p = 0.001; 95% CI: 2.830-5.697) and 
7.31 times on day 28 (p = 0.00117; 95% 
CI: 2.830-5.697) compared with control. 
Although, there was an increase 1.26 
times of miRNA-21 expression after 
intervention with BM type stent on day 28 
compared with that on day7, however it 
was not significantly different (p=0.092).
Gibbons and Dzau12 found that 
the miRNA-21 expression increased 
after vascular injury lead proliferative 
effect on vascular smooth muscle cells. 
Neointimal hyperplasia is characterized 
by the proliferation and migration of 
vascular smooth muscle cells. It is also 
shown by increasing in the extracellular 
matrix, which can lead in narrowing and 
blockage of the blood vessels lumen.3 
Then, miRNA-21 expression increases 
in tissues of human patients who 
experience in stent restenosis compared 
with specimens of coronary heart disease 
patients who are not deployed with 
stents.3 A study conucted by Halliday13 
showed the important role of miRNA-21 
in the occurrence of in stent restenosis. 
Moreover, by removing the gene from 
miRNA-21, it is shown to reduce the 
incidence of in stent restenosis through 
the proliferation and migration response 
of vascular smooth muscle cells and also 
change the immunity function of the cell.
miRNA-21 through its suppression 
function has practical implications 
in increasing cell proliferation, 
inflammation, cell replication, abnormal 
metabolism, angiogenesis, apoptosis 
avoidance, immune destruction 
and suppressor growth. Specifically 
miRNA-21 strongly influences the 
apoptosis process.14 miRNA-21 plays 
a large role in vascular inflammation 
stimulation and post-lesion remodeling 
due to the deployment of stents in pigs.7 
Furthermore, anti miRNA-21 inhibits the 
proliferation of vascular smooth muscle 
cells both in vitro and in vivo.3 miRNA-21 
has a molecular target of PTEN, BMPR2, 
WWP1, YOD1, and SATB1 which have the 
function as proliferation inhibition of 
vascular smooth muscle cells. miRNA-21 
suppresses the target so that the 
proliferation process goes continuously 
without any inhibition.15 miRNA-21 also 
has an important influence in increasing 
IL-6. Expression of miRNA-21 increased 
in inflammatory tissue with increased 
IL-6 levels compared to control tissue, 
so it was concluded that miRNA-21 has a 
role in the inflammatory process.16 This 
study also carried out in patients with 
intervertebral disc degeneration. 
In patient with intervertebral disc 
degeneration, there was an increase 
of cytokine IL-6 (125.6 + 34.9 umol/L) 
with increase of  miRNA-21 expression 
compared to healthy group (p < 0.001).16 
Another study proved that miRNA-21 is 
strongly associated with inflammation. 
A strong association between miRNA-21 
expression and inflammatory markers 
of IL-6 and IL-8 suggests that there 
was a positive relationship between 
miRNA-21 function and inflammatory 
effects.11 Following percutaneous 
coronary intervention (PCI), short-
term clopidogrel therapy in addition to 
aspirin leads to greater protection from 
thrombotic complications than aspirin 
alone. Clopidogrel and aspirin treatment 
before stenting is used for protection 
of thrombotic complications. The 
antiplatelet effects of these drugs persists 
for around one week, which corresponds 
to the mature platelet lifespan.17
This study has some limitations 
because we cannot observe all the miRNA 
in which may associate with IL-6 and IL-8 
measurement. We also id not perform 
randomization in rabbits animal model 
since it is not feasible in this study. 
CONCLUSION
This study showed there is an 
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increase of miRNA-21 expression on day 
7 and neo-intimal hyperplasia rise from 
the mild to moderate after intervention 
with BM type stent. Furthermore, on 
day 28, there is an increase of miRNA-21 
expression and neo-intimal hyperplasia 
rise from to moderate to severe. The 
expression of miRNA-21 increased after 
vascular injury lead proliferative effect 
on vascular smooth muscle cells. The 
increase of miRNA-21 is also shown on 
day 7 and day 28 with increase of IL-6 
and IL-8 value. It can be concluded 
that miRNA-21 might have a role in the 
inflammatory process.
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